Showing 221 - 240 results of 796 for search '"Kyoto"', query time: 0.05s Refine Results
  1. 221
  2. 222
  3. 223
  4. 224
  5. 225
  6. 226
  7. 227
  8. 228
  9. 229
  10. 230
  11. 231
  12. 232
  13. 233
  14. 234
  15. 235
  16. 236
  17. 237

    ArfGAP with the SH3 Domain, Ankyrin Repeat and PH Domain 1 Inversely Regulates Programmed Death-Ligand 1 Through Negative Feedback of Phosphorylated Epithelial Growth Factor Recept... by Chiba N, Menju T, Shimazu Y, Toyazaki T, Sumitomo R, Miyamoto H, Tamari S, Nishikawa S, Date H

    Published 2025-01-01
    “…Naohisa Chiba,1 Toshi Menju,1 Yumeta Shimazu,1 Toshiya Toyazaki,1 Ryota Sumitomo,1 Hideaki Miyamoto,1 Shigeyuki Tamari,1,2 Shigeto Nishikawa,1 Hiroshi Date1 1Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan; 2Department of Thoracic Surgery, Shizuoka City Shizuoka Hospital, Shizuoka, JapanCorrespondence: Toshi Menju, Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, 54 Shigoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan, Tel +81-757514975, Email toshimnj@kuhp.kyoto-u.ac.jpBackground: Signaling pathways centered on the G-protein ADP-ribosylation factor 6 (Arf6) and its downstream effector ArfGAP with the SH3 Domain, Ankyrin Repeat and PH Domain 1 (AMAP1) drive cancer invasion, metastasis, and therapy resistance. …”
    Get full text
    Article
  18. 238
  19. 239
  20. 240